Data compiled by Redley Lamar · ChainSifter Intelligence
0Suppliers
6Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Puma Biotechnology, Inc. (PBYI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
9Total relationships
4Distinct source URLs
5High confidence
0.800Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Puma Biotechnology, Inc. Suppliers
No suppliers on recordPuma Biotechnology, Inc. does not appear to disclose named supplier relationships in its verified regulatory filings, or upstream suppliers have not yet been identified. Our system processes new filings continuously.
Puma Biotechnology, Inc. Customers
Ticker
Name
Confidence
Evidence
SIGNIFICANT-CUSTOMERS
SIGNIFICANT-CUSTOMERS
92%
We depend on a limited number of customers for a significant amount of our total revenue, and if we lose any of our significant customers, our business could be harmed.
SPECIALTY-PHARMACIES
SPECIALTY-PHARMACIES
90%
The Company sells NERLYNX to a limited number of specialty pharmacies and specialty distributors in the United States.
TKPHF
Takeda Pharmaceutical Company Limited
72%
tigational new drugs that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing appro…
TKPHF
Takeda Pharmaceutical Company Limited
72%
Reciprocal relationship from TKPHF graph: Reciprocal relationship from PBYI graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from PBYI graph: tigational new drugs that could d…
PRESENTATION-PUMA-BIOTECHNOLOGY-INC
PRESENTATION-PUMA-BIOTECHNOLOGY-INC
62%
unicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. Estimate of certain variable consideration …
SECURITIES-INVESTOR-PROTECTION-CORPORATION
SECURITIES-INVESTOR-PROTECTION-CORPORATION
62%
ivable, net. The Company’s cash and cash equivalents and restricted cash in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at Ma…
Puma Biotechnology, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
PBYI-DEBT
Debt stack $11.3M
90%
Market cache reports total debt of $11.3M.
PBYI-DEBT-11677
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2013-12-31.
Puma Biotechnology, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Puma Biotechnology, Inc..
Puma Biotechnology, Inc. Ownership
Holder
Name
Confidence
Evidence
PBYI-OWNER-ACORN-CAPITAL-ADVISORS-LLC
ACORN CAPITAL ADVISORS, LLC
90%
13F overlay lists ACORN CAPITAL ADVISORS, LLC as top holder; 158 tracked holders.
Puma Biotechnology, Inc. Extended Supply Chain Network
